Patent ID: 9737515
Date: 2017-08-22
CPC Classifications: A61K

Claim:
1. A pharmaceutical composition for inhibiting tumor growth of an ACSL4-expressing tumor comprising a combination of: i) a first component which is an ACSL4 inhibitor which is rosiglitazone; and ii) a second component consisting of an ER inhibitor the ER inhibitor being selected from the group consisting of tamoxifen, bazedoxifene, lasofoxifene, ormeloxifene, raloxifene, clomifene, 4-OH-tamoxifen, toremifene, afimoxifen, endoxifen, idoxifen, droloxifen, N-demethyl-droloxifen, cis-tamoxifen, desethyl-tamoxifen, N-desmethyl-tamoxifen, tamoxifen citrate, dihydro-tamoxifen, iodo-tamoxifen, 4-chlorotamoxifen, 4-methyl-tamoxifen, 4-fluoro-tamoxifen, 2-methyl-4-hydroxy-tamoxifen, deamino-hydroxy-tamoxifen, 4-hydroxy-deamino-hydroxy-tamoxifen and 4-hydroxy-N-demethyl-tamoxifen.